Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR5A2 | O00482 | 1/20 | 1.00 |
| ▸ | NR5A1 | Q13285 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | FABP3 | P05413 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | PTAFR | P25105 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimyristoylphosphatidylcholine SCHEMBL244839 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL10498112 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL37475 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234790 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL22693933 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL236969 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL231824 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL2036043 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL24563 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Colfosceril Palmitate SCHEMBL2734250 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712950-A2 | IONIZABLE AMINE LIPIDS | Intellia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| EP-4665314-A1 | LIPID NANOPARTICLE CONTAINING PORPHYRIN FOR THE DELIVERY OF RNA | University Health Network (CA) | 2025-12-24 | — | — | EP | claimed |
| WO-2025226857-A2 | COMPOSITIONS AND METHODS FOR TREATING HYPOXIA-RELATED CONDITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-30 | — | — | WO | claimed |
| WO-2025132906-A1 | FOCUSED ULTRASOUND THERMAL ABLATION WITH THERMAL ENHANCERS | BRACCO SUISSE SA (CH) | 2025-06-26 | — | — | WO | claimed |
| US-20250177503-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-06-05 | — | — | US | claimed |
| EP-4482511-A2 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | The Regents of The University of Michigan (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2024243031-A2 | IONIZABLE AMINE LIPIDS | INTELLIA THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | WO | claimed |
| US-20240382626-A1 | IRRADIATION AMENABLE LIPOSOMAL DYE AGGREGATES AND METHODS OF SYNTHESIS AND USE THEREOF | UNIV TEXAS (US) | 2024-11-21 | — | — | US | claimed |
| WO-2024168439-A1 | LIPID NANOPARTICLE CONTAINING PORPHYRIN FOR THE DELIVERY OF RNA | UNIVERSITY HEALTH NETWORK (CA) | 2024-08-22 | — | — | WO | claimed |
| US-20130177637-A1 | METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES | PACIRA PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | claimed |
| US-20110250264-A1 | METHOD FOR FORMULATING LARGE DIAMETER SYNTHETIC MEMBRANE VESICLES | PACIRA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | claimed |
| EP-2322143-A1 | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes | Pacira Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| US-20090092661-A1 | LIPOSOME COMPOSITIONS FOR IN VIVO ADMINISTRATION OF BORONIC ACID COMPOUNDS | ALZA CORPORATION | 2009-04-09 | — | — | US | claimed |
| EP-0971699-A4 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SKYEPHARMA INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-6241999-B1 | SUBSTITUTING FIRST AMPHIPATHIC LIPID WITH ONE HAVING A SIMILIAR STRUCTURE BUT MORE C ATOMS | SKYEPHARMA, INC. | 2001-06-05 | — | — | US | claimed |
| US-6193998-B1 | INCREASING EFFICIENCY USING MULTIVESICULAR LIPOSOMES CONTAINING PHOSPHOLIPIDS | SKYEPHARMA INC. | 2001-02-27 | — | — | US | claimed |
| US-6171613-B1 | REPLACING AMPHIPATHIC LIPIDS | SKYEPHARMA INC. | 2001-01-09 | — | — | US | claimed |
| EP-0971699-A1 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SkyePharma Inc. (US) | 2000-01-19 | — | — | EP | claimed |
| WO-1998033483-A1 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SKYEPHARMA, INC. (US) | 1998-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092661-A1 | LIPOSOME COMPOSITIONS FOR IN VIVO ADMINISTRATION OF BORONIC ACID COMPOUNDS | LIPA, LPAR6, ABHD6 | SMN1; SMN2 388/4885NR5A2 4575/4885NR5A1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.